Ridge Bio key facts
as of Oct 2026- Developer of precision enzymes and targeted drug delivery systems designed to advance the development of precision medicines.
- Ridge Bio is valued at approximately $65.0M as of Oct 2026 (last reported valuation).
- It has raised $24.7M; the latest was Seed Round ($24.7M) in Sep 2025.
- Notable investors include Sutter Hill Ventures, Overlap Holdings.
- Status: Privately Held (backing).
Ridge Bio's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·Watch Ridge Bio: the Monday email on marks, rounds and moves
Ridge Bio funding rounds
No funding rounds for Ridge Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ridge Bio
2Ridge Bio valuation
Ridge Bio's last reported valuation was $65 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Ridge Bio investors
2 investors are on record for Ridge Bio, including Sutter Hill Ventures and Overlap Holdings. By type, the record holds 2 venture capital firms.
About Ridge Bio
Developer of precision enzymes and targeted drug delivery systems designed to advance the development of precision medicines. The company offers an experiment-informed artificial intelligence platform that supports antibody-drug conjugates, chimeric antigen receptor T lymphocyte therapies, nucleic acid delivery, biocatalysts, radiotherapies, and enzyme-based therapeutics, enabling pharmaceutical researchers to improve specificity and therapeutic performance.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2024
- Website
- ridgebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.